ABO-incompatible allogeneic hematopoietic stem cell transplantation following reduced-intensity conditioning: Close association with transplant-associated microangiopathy

Powles, 1980, Cyclosporine to prevent graft-versus-host disease in man after allogeneic bone marrow transplantation, Lancet, 1, 327, 10.1016/S0140-6736(80)90881-8 Daly, 2002, Transplantation-associated thrombotic microangiopathy: Twenty-two years later, Bone Marrow Transplant, 30, 709, 10.1038/sj.bmt.1703710 Pettitt, 1994, Thrombotic microangiopathy following bone marrow transplantation, Bone Marrow Transplant, 14, 495 Zeigler, 1995, Bone marrow transplant-associated thrombotic microangiopathy: A case series, Bone Marrow Transplant, 15, 247 Fuge, 2001, The clinical features, risk factors and outcome of thrombotic thrombocytopenic purpura occurring after bone marrow transplantation, Br J Haematol, 113, 58, 10.1046/j.1365-2141.2001.02699.x Rutuu, 2002, Thrombotic thrombocytopenic purpura occurring after allogeneic stem cell transplantation: a survey of the European Group for Blood and Marrow Transplantation (EBMT), Br J Haematol, 118, 1112, 10.1046/j.1365-2141.2002.03721.x George, 2004, Thrombotic thrombocytopenic purpura -hemolytic uremic syndrome following allogeneic HPC transplantation: a diagnostic dilemma, Transfusion, 44, 294, 10.1111/j.1537-2995.2004.00700.x Chappell, 1988, Haemolytic uraemic syndrome after bone marrow transplantation: an adverse effect of total body irradiation?, Bone Marrow Transplant, 3, 339 Holler, 1989, Microangiopathy in patients on cyclosporine prophylaxis who developed acute graft-versus-host disease after HLA-identical bone marrow transplantation, Blood, 73, 2018, 10.1182/blood.V73.7.2018.2018 Kalhs, 1995, Association with cyclosporine and methylprednisolone for graft-versus-host disease prophylaxis, Transplantation, 60, 949, 10.1097/00007890-199511000-00012 Khouri, 1998, Transplant lite: Induction of graft-versus-malignancy using fludarabine based non-ablative chemotherapy and allogeneic blood progenitor cell transplantation as treatment for lymphoid malignancies, J Clin Oncol, 8, 2817, 10.1200/JCO.1998.16.8.2817 Slavin, 1998, Non-myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for the treatment of malignant and nonmalignant hematologic diseases, Blood, 91, 756, 10.1182/blood.V91.3.756 McSweeney, 2001, Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects, Blood, 97, 3390, 10.1182/blood.V97.11.3390 Bensinger, 1982, ABO-incompatible marrow transplants, Transplantation, 33, 427, 10.1097/00007890-198204000-00017 Benjamin, 1999, ABO incompatibility as an adverse risk factor for survival after allogeneic bone marrow transplantation, Transfusion, 39, 179, 10.1046/j.1537-2995.1999.39299154733.x Worel, 2003, ABO mismatch increases transplant-related morbidity and mortality in patients given nonmyeloablative allogeneic HPC transplantation, Transfusion, 43, 1153, 10.1046/j.1537-2995.2003.00465.x Bolan, 2001, Delayed donor red cell chimerism and pure red cell aplasia following major ABO-incompatible nonmyeloablative hematopoietic stem cell transplantation, Blood, 98, 1687, 10.1182/blood.V98.6.1687 Bolan, 2001, Massive immune hemolysis after allogeneic peripheral blood stem cell transplantation with minor ABO incompatibility, Br J Haematol, 112, 787, 10.1046/j.1365-2141.2001.02587.x Worel, 2002, Severe immune hemolysis after minor ABO-incompatible allogeneic peripheral blood stem cell transplantation occurs more frequently after nonmyeloablative than myeloablative conditioning, Transfusion, 42, 1293, 10.1046/j.1537-2995.2002.00209.x Shimoni, 2004, Thrombotic microangiopathy after allogeneic stem cell transplantation in the era of reduced-intensity conditioning: the incidence is not reduced, Biol Blood Marrow Transplant, 10, 484, 10.1016/j.bbmt.2004.03.002 Nakamae, 2006, Risk factor analysis for thrombotic microangiopathy after reduced-intensity or myeloablative allogeneic hematopoietic stem cell transplantation, Am J Hematol, 81, 525, 10.1002/ajh.20648 Schmid, 2006, Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation, Blood, 108, 1092, 10.1182/blood-2005-10-4165 Cull, 2000, Preliminary experience of allogeneic stem cell transplantation for lymphoproliferative disorder using BEAM-CAMPATH conditioning: an effective regimen with low procedure-related toxicity, Br J Haematol, 108, 754, 10.1046/j.1365-2141.2000.01879.x Dreger, 2003, Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning, Leukemia, 17, 841, 10.1038/sj.leu.2402905 Winston, 1991, Prevention and treatment of cytomegalovirus infection and disease after bone marrow transplantation in the 1990s, Bone Marrow Transplant, 8, 7 Keil, 2003, Transplantation, 76, 230, 10.1097/01.TP.0000071862.42835.76 Przepiorka, 1995, Consense conference on acute GvHD grading, Bone Marrow Transplant., 15, 825 Sullivan, 1981, Chronic graft-versus-host disease in 52 patients: adverse natural course and successful treatment with combination immunosuppression, Blood, 57, 267, 10.1182/blood.V57.2.267.267 Ho, 2005, Blood and marrow transplant clinical network toxicity consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation, Biol Blood Marrow Transplant, 11, 571, 10.1016/j.bbmt.2005.06.001 Stussi, 2002, Consequences of ABO incompatibility in allogeneic hematopoietic stem cell transplantation, Bone Marrow Transplant, 30, 87, 10.1038/sj.bmt.1703621 Bacigalupo, 1988, ABO compatibility and acute graft-versus-host disease following allogeneic bone marrow transplantation, Transplantation, 45, 1091, 10.1097/00007890-198806000-00018 Mueller, 2006, Major ABO-incompatible hematopoietic stem cell transplantation: study of post-transplant pure red cell aplasia and endothelial cell chimerism, Xenotransplant, 13, 126, 10.1111/j.1399-3089.2006.00281.x Meroni, 2005, Humoral autoimmunity against endothelium: theory or reality?, Trends Immunol, 26, 275, 10.1016/j.it.2005.03.006 Mielcarek, 2003, Graft-versus-host disease after nonmyeloablative versus conventional hematopoietic stem cell transplantation, Blood, 102, 756, 10.1182/blood-2002-08-2628 Biedermann, 2002, Endothelial injury mediated by cytotoxic T lymphocytes and loss of microvessels in chronic graft versus host disease, Lancet, 359, 2078, 10.1016/S0140-6736(02)08907-9 Eissner, 2002, Fludarabine induces apoptosis, activation and allogenicity in human endothelial and epithelial cell: protective effect of defibrotide, Blood, 100, 334, 10.1182/blood.V100.1.334 Rock, 1991, Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura, N Engl J Med, 325, 393, 10.1056/NEJM199108083250604 Llamas, 1997, Management of thrombotic microangiopathy following allogeneic transplantation; what is the role of plasma exchange?, Bone Marrow Transplant, 20, 305, 10.1038/sj.bmt.1700889